{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', 'Table 2:', 'Bleeding Episode Assessments - Unscheduled Visit', 'Predose', 'Postdose', 'Postdose', '10 min (=5 min)', '60 min (=5 min)', 'Directed Physical', 'X', 'Examination', 'Vital Signs', 'X', 'AT', 'X', 'FVIII/IX Levels', 'X', 'X', 'X', 'TG', 'X', 'X', 'X', 'Coagulation', 'X', 'X', 'X', 'Hematology', 'X', 'X', 'X', 'Exploratory', 'X', 'X', 'Coagulation', 'Optional Imaging', 'X', 'Abbreviations: AT=antithrombin; BPAs=bypassing agents; FVIII=factor VIII; FIX=factor IX; TG=thrombin generation', 'a See Section 7.5.3 for assessments to be performed during a directed physical examination.', 'b', 'After specified analyses are run, residual samples may be stored for up to 15 years from last patient last visit, or as per local', 'regulations, and used for further study of biomarkers related to hemophilia and associated conditions, investigation of emerging', 'safety issues, or the development of fitusiran.', 'c Investigator to consider confirmation of bleed via ultrasound or other imaging modality at clinical study centers where', 'appropriate equipment and staff with related expertise is available.', 'd', 'If the patient presents following administration of factor or BPAs at home and within 48 hours of the dose, and no further', 'treatment is given at the center, AT and the postdose assessments should be obtained in a single draw at any time during the', 'visit.', 'Property of the Sanofi Group - strictly confidential', '16', '(electronic 1.0)']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', 'TABLE OF CONTENTS', 'DOCUMENT HISTORY', '2', 'OVERALL RATIONALE FOR THE AMENDMENT', '2', 'PROTOCOL SYNOPSIS', '6', 'TABLE OF CONTENTS', '17', 'LIST OF TABLES', '22', 'LIST OF FIGURES', '22', 'LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS', '23', '1.', 'INTRODUCTION', '26', '1.1.', 'Disease Overview', '26', '1.2.', 'Fitusiran (SAR439774)', '27', '1.2.1.', 'Summary of Nonclinical Data With Fitusiran', '27', '1.2.2.', 'Summary of Clinical Data With Fitusiran', '28', '1.2.2.1.', 'Summary of Efficacy', '29', '1.2.2.2.', 'Summary of Safety', '30', '1.2.2.3.', 'Summary of Pharmacokinetic and Pharmacodynamic Effects in', 'ALN-AT3SC-001 and ALN-AT3SC-002', '31', '1.3.', 'Study Design Rationale', '31', '1.4.', 'Dose Rationale', '32', '1.5.', 'Benefit-Risk Assessment', '33', '2.', 'OBJECTIVES', '33', '2.1.', 'Primary Objective', '33', '2.2.', 'Secondary Objectives', '34', '2.3.', 'Exploratory Objectives', '34', '3.', 'ENDPOINTS', '34', '3.1.', 'Primary Endpoint', '34', '3.2.', 'Secondary Endpoints', '34', '3.3.', 'Exploratory Endpoints', '35', '3.4.', 'Safety Endpoint', '35', '4.', 'INVESTIGATIONAL PLAN', '35', '4.1.', 'Summary of Study Design', '35', '4.2.', 'Duration of Treatment', '37', 'Property of the Sanofi Group - strictly confidential', '17', '(electronic 1.0)']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', '4.3.', 'Number of Patients', '37', '4.4.', 'Method of Assigning Patients to Treatment Groups', '37', '4.5.', 'Blinding', '38', '4.6.', 'Study Steering Committee', '38', '4.7.', 'Data Monitoring Committee', '38', '5.', 'SELECTION AND WITHDRAWAL OF PATIENTS', '38', '5.1.', 'Inclusion Criteria', '38', '5.2.', 'Exclusion Criteria', '39', '5.3.', 'Removal from Therapy or Assessment', '40', '5.3.1.', 'Discontinuation of Investigational Medicinal Product', '41', '5.3.2.', 'Withdrawal From Study', '41', '6.', 'TREATMENTS', '42', '6.1.', 'Treatments Administered', '42', '6.2.', 'Investigational Medicinal Product', '42', '6.2.1.', 'Description', '42', '6.2.2.', 'Dose and Administration', '42', '6.2.3.', 'Dose Modifications', '42', '6.2.3.1.', 'LFT Criteria for Withholding, Monitoring and Stopping Fitusiran Dosing', '42', '6.2.4.', 'Preparation, Handling, and Storage', '45', '6.2.5.', 'Packaging and Labeling', '45', '6.2.6.', 'Accountability', '45', '6.3.', 'Concomitant Medications', '45', '6.3.1.', 'Management of Bleeding Episodes', '46', '6.3.1.1.', 'Bleeding Episode Management Recommendations for Patients in the On-', 'Demand Treatment Arm (Patients Not Receiving Fitusiran)', '46', '6.3.1.2.', 'Bleeding Episode Management Recommendations for Patients in the', 'Fitusiran Treatment Arm', '46', '6.3.1.3.', 'Bleeding Episode Management Following Discontinuation of Fitusiran', '50', '6.3.2.', 'Other Concomitant Medications', '50', '6.4.', 'Assessment of Coagulation Parameters at the Time of a Bleed', '50', '6.5.', 'Monitoring and Management of Thrombotic Events', '50', '6.6.', 'Elective and/or Emergency Surgery', '51', '6.7.', 'Management of Sepsis', '52', 'Property of the Sanofi Group - strictly confidential', '18', '(electronic 1.0)']\n\n###\n\n", "completion": "END"}